Pharmaceutical Toremifene Citrate For Breast Cancer Treatment CAS 89778-27-8

Basic Information
Place of Origin: China
Brand Name: Senwayer
Certification: ISO, 9001, USP
Model Number: 89778-27-8
Minimum Order Quantity: 10g
Price: Discount is possible if your order is big enough
Packaging Details: 10g, 20g, 50g , 100g, 500g. 1kg, 10kg
Delivery Time: within 2 working days
Payment Terms: T/T in advance, Money Gram, Western Union, Bank Transfer.
Supply Ability: 50KG / Month
Detail Information
CAS: 89778-27-8 Alias: Fareston , Toremifene Citrate
Apparence: Almost White Crystalline Powder Purity: 99%
Usage: Breast Cancer Cure Grade: Pharma Grade
High Light:

natural anti estrogen supplements


natural estrogen blocker

Product Description

Toremifene Citrate Breast Cancer Cure and Protection Fareston 89778-27-8 SERM


Quick detail

Toremifene Citrate
CAS No.: 89778-27-8
Synonyms: 2-[4-[(Z)-4-chloro-1,2-diphenylbut-1-enyl]phenoxy]-N,N-dimethylethanamine,2-hydroxypropane-1,2,3-tricarboxylic acid;
Formula: C32H36ClNO8
Exact Mass: 597.21300
Molecular Weight: 598.08300
PSA: 144.60000
LogP: 4.96650
Appearance & Physical State: White or almost white powder
Density: 1.045g/cm3
Melting Point: 158-164ºC
Boiling Point: 535.1ºC at 760 mmHg
Flash Point: 277.4ºC
Refractive Index: 1.416-1.418
Storage Condition: -20ºC Freezer
Half Life: 5 days
Detection Time: Unknown
Anabolic Rating: N/A
Androgenic Rating:




FARESTON  is an estrogen agonist/antagonist indicated for the treatment of metastatic breast cancer in postmenopausal women with estrogen-receptor positive or unknown tumors. 



60 mg once daily, orally


60 mg tablet is round, convex, unscored, uncoated, and white, or almost white, identified with TO 60 embossed on one side.


When This Medicine Should Not Be Used:

You should not use this medicine if you have had an allergic reaction to toremifene citrate, or if you are pregnant. You should not use this medicine if you have a low potassium or magnesium in the blood; or heart rhythm problems (such as congenital or acquired long QT syndrome). This medicine should not be given to men and children.


Toremifene Citrate Description:

Toremifene (also known under its brand and trade name of Fareston) is a member of a category, family, and class of drugs that are known as SERMs (Selective Estrogen Receptor Modulators). SERMs fall under an even broader category of drugs that are known as anti-estrogens, and the cousin family of SERMs (that also fall under anti-estrogens) are aromatase inhibitors, commonly abbreviated as AIs.


SERMs include compounds such as Toremifene, Nolvadex(Tamoxifen), and Clomid (Clomiphene Citrate). Aromatase inhibitors (AIs) include compounds such as Arimidex (Anastrozole), Aromasin (Exemestane), and Letrozole (Femara).


Although the two fall under the category of anti-estrogens, they are both sub-categories that branch off into their own families, as SERMs and AIs differ greatly in their mechanism of action within the human body concerning how they control or block Estrogen. There has been much misunderstanding and misconception in previous decades as to what each of these do, and this should always be first clarified to the reader before describing Toremifene.


Fareston Application

Toremifene is used in postmenopausal women to treat breast cancer that has spread to other parts of the body (metastatic breast cancer). It is usually used to treat cancerthat needs estrogen, a female hormone, in order to grow (estrogen-receptor positive). Toremifene is a nonsteroidal antiestrogen that blocks the effects of estrogen in thebreast tissue, thereby slowing or stopping the growth of cancer.


SERMs are true ‘Estrogen blockers’, while AIs are not. SERMs act to block the activity of Estrogen at their target receptor sites in different tissues (mainly breast tissue), and they do this by binding more strongly to the Estrogen receptors in these tissues than Estrogen itself, effectively taking the spot that Estrogen normally would. The SERMs will remain bound to the receptor site and remain inert (they will not activate the receptors or perform any actions) This results in the inability for Estrogen to bind to these receptors (as they are already occupied by the SERM).


While SERMs block Estrogenic activity at certain receptor sites, SERMs can and do also act as estrogens themselves in other receptor sites in other tissues in the body (such as in the liver, which can be beneficial). This is known as Estrogen agonist and Estrogen antagonist activity. In any case, SERMs do not serve to lower overall total circulating blood plasma levels of Estrogen in the body – they merely block its activity in certain tissues.


Aromatase inhibitors (AIs) are instead the compounds that will reduce total circulating levels of Estrogen in the body by way of binding to the enzyme responsible for the conversion (aromatization) of androgens into Estrogen. This enzyme is known as aromatase. AIs are more attractive as a substrate to the aromatase enzyme than the aromatase enzyme’s traditional substrate targets, which are androgens (such as Testosterone).


The result is that the aromatase enzyme is occupied with the AI, and therefore cannot engage in chemical reactions with androgens. This results in the inability for Estrogen to be manufactured at its root source, and therefore Estrogen levels as a whole are reduced in the body.

How to use toremifene

Take this medication by mouth with or without food, usually once daily or as directed by your doctor. Dosage is based on your medical condition and response to therapy.

Use this medication regularly to get the most benefit from it. To help you remember, take it at the same time each day.

Avoid eating grapefruit or drinking grapefruit juice while using this medication unless your doctor or pharmacist says you may do so safely. Grapefruit can increase the chance of side effects with this medicine. Ask your doctor or pharmacist for more details.

Since this drug can be absorbed through the skin and lungs, women who are pregnant or who may become pregnant should not handle this medication or breathe the dust from the tablets.


Related ANTI-ESTROGEN product: 

Tamoxifen Citrate (Nolvadex) CAS:54965-24-1
Clomiphene citrate CAS:50-41-9
Toremifene citrate CAS:50-41-9
Exemestane(Aromasin) CAS:107868-30-4
Anastrozole (Arimidex) CAS:120511-73-1
Letrazole(Femara) CAS:120511-73-1
Methoxydienone CAS:2322-77-2
Estradiol CAS:50-28-2
Norgestrel CAS:6533-00-2


Warnings and Precautions

  • Fareston has been shown to prolong the QT interval. Caution should be exercised in patients with congestive heart failure, hepatic impairment and electrolyte abnormalities. In patients at increased risk, ECGs should be obtained at baseline and as clinically indicated.
  • Hypercalcemia and tumor flare have been reported during the first weeks of treatment with Fareston in some breast cancer patients with bone metastases. If hypercalcemia is severe, Fareston treatment should be discontinued.
  • Patients with preexisting endometrial hyperplasia should not be given long-term Fareston treatment, and patients at high risk for endometrial cancer should be closely monitored.
  • Patients with a history of thromboembolic diseases should not be treated with Fareston.
  • Leukocyte and platelet counts should be monitored when using Fareston in patients with leukopenia and thrombocytopenia.
  • Fareston can cause fetal harm when administered to a pregnant woman.
  • Fareston is only indicated for postmenopausal women. However, premenopausal women prescribed Fareston should use effective nonhormonal contraception and should be apprised of the potential hazard to the fetus should pregnancy occur.

Contact Details
Abby Xiang

Phone Number : +8617764031156

WhatsApp : +8617764031156